Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit
April 20 2022 - 7:00AM
Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the
"Company”) today announced that Michael J. Newman, Ph.D., Founder
and Chief Scientific Officer, will present at the 2nd Annual
Chronic HBV Drug Development Summit taking place from April 25-27,
2022 in Boston, MA.
Presentation Details:
- Title: Driving Pre-Clinical Anti-HBV Activity
With a Novel Multi-TLR Agonist Therapeutic Vaccine
- Date and Time: April 27, 2022 at 12:00 PM
ET
The 2nd Chronic HBV Drug Development Summit is
dedicated to advancing direct antiviral and immunotherapy pipelines
in combination therapy paradigms.
About Indaptus Therapeutics
Indaptus Therapeutics has evolved from more than
a century of immunotherapy advances. The Company's approach is
based on the hypothesis that efficient activation of both innate
and adaptive immune cells and associated anti-tumor and
anti-viral immune responses will require a multi-targeted
package of immune system activating signals that can be
administered safely intravenously. Indaptus' patented
technology is composed of single strains of attenuated
and killed, non-pathogenic, Gram-negative bacteria, with
reduced i.v. toxicity, but largely uncompromised ability to
prime or activate many of the cellular components of innate
and adaptive immunity. This approach has led to broad
anti-tumor and anti-viral activity, including safe, durable
anti-tumor response synergy with each of five different classes of
existing agents, including checkpoint therapy, targeted
antibody therapy and low-dose chemotherapy in preclinical models.
Tumor eradication by Indaptus technology has been demonstrated to
produce both innate and adaptive immunological memory and,
importantly, does not require provision of or targeting a
specific tumor antigen in pre-clinical models. Indaptus technology
has also produced significant single agent activity against chronic
hepatitis B virus (HBV) and chronic human immunodeficiency virus
(HIV) infections in pre-clinical models. Indaptus has carried out
successful GMP manufacturing of its lead clinical oncology
candidate, Decoy20, and has completed other IND enabling
studies.
Forward-Looking Statements
This press release contains forward-looking
statements with the meaning of the Private Securities Litigation
Reform Act. These include statements regarding management's
expectations, beliefs and intentions regarding, among other things,
our product development efforts, business, financial condition,
results of operations, strategies, plans and prospects.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. Forward-looking statements relate to
anticipated or expected events, activities, trends or results as of
the date they are made. Because forward-looking statements relate
to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause our
actual results to differ materially from any future results
expressed or implied by the forward-looking statements. Many
factors could cause actual activities or results to differ
materially from the activities and results anticipated in
forward-looking statements, including, but not limited to, the
following: our plans to develop and potentially commercialize its
technology, the timing and cost of our planned investigational new
drug application and any clinical trials, the completion and
receiving favorable results in any clinical trials, Indaptus'
ability to obtain and maintain regulatory approval of any product
candidate, our ability to protect and maintain its intellectual
property and licensing arrangements, our ability to develop,
manufacture and commercialize its product candidates, the risk of
product liability claims, the availability of reimbursement, the
influence of extensive and costly government regulation, and our
estimates regarding future revenue, expenses capital requirements
and the need for additional financing. More detailed information
about the risks and uncertainties affecting us is contained under
the heading “Risk Factors” included in our most recent Annual
Report on Form 10-K filed with the SEC on March 21, 2022, and in
other filings that we have made and may make with the Securities
and Exchange Commission in the future. All forward-looking
statements speak only as of the date of this press release and are
expressly qualified in their entirety by the cautionary statements
included in this press release. We undertake no obligation to
update or revise forward-looking statements to reflect events or
circumstances that arise after the date made or to reflect the
occurrence of unanticipated events, except as required by
applicable law.
Investor Contact:Will O'Connor Stern
Investor Relations +1
212-362-1200 will.oconnor@sternir.com
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Indaptus Therapeutics (NASDAQ:INDP)
Historical Stock Chart
From Jul 2023 to Jul 2024